Exact Mass: 522.1948464
Exact Mass Matches: 522.1948464
Found 225 metabolites which its exact mass value is equals to given mass value 522.1948464
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Ticagrelor
Ticagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011. B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent > C190801 - P2Y12 Inhibitor D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.
Prednisolone phthalate
2-[4,5-Dimethoxy-5-(3-phenyl-trans-allyl)cyclohexa-3,6-dien-2-on-1-ylmethyl]-5-hydroxy-6-methoxy-3-phenylbenzofuran
5-Hydroxy-7-methoxy-3,4-diacetoxy-6-(6,6-dimethyl-2-oxo-cyclohexylmethyl)flavone
1beta-(3-furanoyloxy)-9alpha-benzoyloxy-8beta-acetoxy-2-oxo-3-enedihydro-beta-agarofuran
2-[4,5-Dimethoxy-2-(3-phenyl-trans-allyloxy)benzyl]-5-hydroxy-6-methoxy-3-phenylbenzofuran
Azatadine maleate
D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist Azatadine bimaleate is an inhibitor of histamine receptors and choline receptors with IC50s of 6.5 nM and 10 nM respectively.
Ticagrelor
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent > C190801 - P2Y12 Inhibitor D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.
C22H34O14_Hexitol, 2,6-anhydro-, 5-[4-(beta-D-glucopyranosyloxy)-2-methylenebutanoate] 1-(4-hydroxy-2-methylenebutanoate)
Cys His Thr Tyr
Cys His Tyr Thr
Cys Met Asn Arg
C18H34N8O6S2 (522.2042624000001)
Cys Met Arg Asn
C18H34N8O6S2 (522.2042624000001)
Cys Asn Met Arg
C18H34N8O6S2 (522.2042624000001)
Cys Asn Arg Met
C18H34N8O6S2 (522.2042624000001)
Cys Asn Thr Trp
Cys Asn Trp Thr
Cys Gln Ser Trp
Cys Gln Trp Ser
Cys Arg Met Asn
C18H34N8O6S2 (522.2042624000001)
Cys Arg Asn Met
C18H34N8O6S2 (522.2042624000001)
Cys Ser Gln Trp
Cys Ser Trp Gln
Cys Thr His Tyr
Cys Thr Asn Trp
Cys Thr Trp Asn
Cys Thr Tyr His
Cys Trp Asn Thr
Cys Trp Gln Ser
Cys Trp Ser Gln
Cys Trp Thr Asn
Cys Tyr His Thr
Cys Tyr Thr His
Asp Glu Pro Tyr
Asp Glu Tyr Pro
Asp Pro Glu Tyr
Asp Pro Tyr Glu
Asp Tyr Glu Pro
Asp Tyr Pro Glu
Glu Asp Pro Tyr
Glu Asp Tyr Pro
Glu Pro Asp Tyr
Glu Pro Tyr Asp
Glu Tyr Asp Pro
Glu Tyr Pro Asp
His Cys Thr Tyr
His Cys Tyr Thr
His Thr Cys Tyr
His Thr Tyr Cys
His Tyr Cys Thr
His Tyr Thr Cys
Met Cys Asn Arg
C18H34N8O6S2 (522.2042624000001)
Met Cys Arg Asn
C18H34N8O6S2 (522.2042624000001)
Met Met Asn Gln
Met Met Gln Asn
Met Asn Cys Arg
C18H34N8O6S2 (522.2042624000001)
Met Asn Met Gln
Met Asn Gln Met
Met Asn Arg Cys
C18H34N8O6S2 (522.2042624000001)
Met Gln Met Asn
Met Gln Asn Met
Met Arg Cys Asn
C18H34N8O6S2 (522.2042624000001)
Met Arg Asn Cys
C18H34N8O6S2 (522.2042624000001)
Asn Cys Met Arg
C18H34N8O6S2 (522.2042624000001)
Asn Cys Arg Met
C18H34N8O6S2 (522.2042624000001)
Asn Cys Thr Trp
Asn Cys Trp Thr
Asn Met Cys Arg
C18H34N8O6S2 (522.2042624000001)
Asn Met Met Gln
Asn Met Gln Met
Asn Met Arg Cys
C18H34N8O6S2 (522.2042624000001)
Asn Gln Met Met
Asn Arg Cys Met
C18H34N8O6S2 (522.2042624000001)
Asn Arg Met Cys
C18H34N8O6S2 (522.2042624000001)
Asn Thr Cys Trp
Asn Thr Trp Cys
Asn Trp Cys Thr
Asn Trp Thr Cys
Pro Asp Glu Tyr
Pro Asp Tyr Glu
Pro Glu Asp Tyr
Pro Glu Tyr Asp
Pro Tyr Asp Glu
Pro Tyr Glu Asp
Gln Cys Ser Trp
Gln Cys Trp Ser
Gln Met Met Asn
Gln Met Asn Met
Gln Asn Met Met
Gln Ser Cys Trp
Gln Ser Trp Cys
Gln Trp Cys Ser
Gln Trp Ser Cys
Arg Cys Met Asn
C18H34N8O6S2 (522.2042624000001)
Arg Cys Asn Met
C18H34N8O6S2 (522.2042624000001)
Arg Met Cys Asn
C18H34N8O6S2 (522.2042624000001)
Arg Met Asn Cys
C18H34N8O6S2 (522.2042624000001)
Arg Asn Cys Met
C18H34N8O6S2 (522.2042624000001)
Arg Asn Met Cys
C18H34N8O6S2 (522.2042624000001)
Ser Cys Gln Trp
Ser Cys Trp Gln
Ser Gln Cys Trp
Ser Gln Trp Cys
Ser Trp Cys Gln
Ser Trp Gln Cys
Thr Cys His Tyr
Thr Cys Asn Trp
Thr Cys Trp Asn
Thr Cys Tyr His
Thr His Cys Tyr
Thr His Tyr Cys
Thr Asn Cys Trp
Thr Asn Trp Cys
Thr Trp Cys Asn
Thr Trp Asn Cys
Thr Tyr Cys His
Thr Tyr His Cys
Trp Cys Asn Thr
Trp Cys Gln Ser
Trp Cys Ser Gln
Trp Cys Thr Asn
Trp Asn Cys Thr
Trp Asn Thr Cys
Trp Gln Cys Ser
Trp Gln Ser Cys
Trp Ser Cys Gln
Trp Ser Gln Cys
Trp Thr Cys Asn
Trp Thr Asn Cys
Tyr Cys His Thr
Tyr Cys Thr His
Tyr Asp Glu Pro
Tyr Asp Pro Glu
Tyr Glu Asp Pro
Tyr Glu Pro Asp
Tyr His Cys Thr
Tyr His Thr Cys
Tyr Pro Asp Glu
Tyr Pro Glu Asp
Tyr Thr Cys His
Tyr Thr His Cys
Vanoxerine dihydrochloride
D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D018765 - Dopamine Uptake Inhibitors D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents D049990 - Membrane Transport Modulators
1,1-(Decane-1,10-diyl)bis[4-aza-1-azoniabicyclo[2.2.2]octane] Dibromide
N-alpha-(2-Naphthylsulfonyl)-N(3-amidino-L-phenylalaninyl)isopipecolinic acid methyl ester
23,26-Dihydroxy-23-(2-hydroxyacetyl)-1,24-dimethyl-3,12-dioxahexacyclo[14.11.0.02,13.05,10.019,27.020,24]heptacosa-2(13),5,7,9,15-pentaene-4,11,14-trione
Baeckea frutescens 6
D001697 - Biomedical and Dental Materials > D003764 - Dental Materials
[3,4-dihydroxy-5-[2-methylidene-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutanoyl]oxyoxan-2-yl]methyl 4-hydroxy-2-methylidenebutanoate
9-[5-Carboxy-2-(ethoxycarbonyl)phenyl]-3,6-bis(ethylamino)-2,7-dimethylxanthenium chloride
[(1R)-2-[(4-chlorophenyl)methyl]-7-methoxy-1-(2-thiazolylmethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
1-(4-fluorophenyl)-3-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]urea
[(1S)-2-[(4-chlorophenyl)methyl]-7-methoxy-1-(2-thiazolylmethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
1-(4-fluorophenyl)-3-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]urea
1-(4-fluorophenyl)-3-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]urea
1-(4-fluorophenyl)-3-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]urea
1-(4-fluorophenyl)-3-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]urea
1-(4-fluorophenyl)-3-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]urea
1-(4-fluorophenyl)-3-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]urea
1-(4-fluorophenyl)-3-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]urea
1-(4-fluorophenyl)-3-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]urea
1-(4-fluorophenyl)-3-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]urea
5-[(E)-2-[(2S,3R,4S)-3-ethenyl-5-methoxycarbonyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-4-yl]ethenyl]-1-ethylpyridin-1-ium-3-carboxylic acid
(2S,3R,4S)-4-[(E)-2-[1-(3-carboxypropyl)pyridin-1-ium-3-yl]ethenyl]-3-ethenyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-5-carboxylic acid
(1R,2S,3R,5S)-3-[7-[[(1R,2R)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
BF 6
An organic heterotetracyclic compound that is 8,12-dihydro-2H,9H-pyrano[2,3-a]xanthene-4,9,11(3H,10H)-trione substituted by methyl groups at positions 6, 8, 8, 10 and 10 and phenyl groups at positions 2 and 12 respectively (the S-enantiomer). It is isolated from the leaves of Baeckea frutescens and exhibits cytotoxicity against leukemia cells.
9,19-dimethoxy-18-methyl-5,13-diphenyl-4,12,14-trioxapentacyclo[11.7.1.0²,¹¹.0³,⁸.0¹⁵,²⁰]henicosa-2(11),3(8),9,15,17,19-hexaen-17-ol
(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1s,4as,7r,7ar)-7-methyl-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyran-4-carboxylate
(2s,12s)-5-hydroxy-6,8,8,10,10-pentamethyl-2,12-diphenyl-3,12-dihydro-2h-1,7-dioxatetraphene-4,9,11-trione
2-[4,5-dimethoxy-2-(3-phenyl-trans-allyloxy)benzyl]-5-hydroxy-6-methoxy-3-phenylbenzo-furan
{"Ingredient_id": "HBIN004226","Ingredient_name": "2-[4,5-dimethoxy-2-(3-phenyl-trans-allyloxy)benzyl]-5-hydroxy-6-methoxy-3-phenylbenzo-furan","Alias": "NA","Ingredient_formula": "C33H30O6","Ingredient_Smile": "COC1=C(C=C(C(=C1)CC2=C(C3=CC(=C(C=C3O2)OC)O)C4=CC=CC=C4)OCC=CC5=CC=CC=C5)OC","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "6275","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
2-[4,5-dimethoxy-5-(3-phenyl-trans-allyl)cyclo-hexa-3,6-dien-2-on-1-ylmethyl]-5-hydroxy-6-methoxy-3-phenylbenzofuran
{"Ingredient_id": "HBIN004227","Ingredient_name": "2-[4,5-dimethoxy-5-(3-phenyl-trans-allyl)cyclo-hexa-3,6-dien-2-on-1-ylmethyl]-5-hydroxy-6-methoxy-3-phenylbenzofuran","Alias": "NA","Ingredient_formula": "C33H30O6","Ingredient_Smile": "COC1=CC(=O)C(=CC1(CC=CC2=CC=CC=C2)OC)CC3=C(C4=CC(=C(C=C4O3)OC)O)C5=CC=CC=C5","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "6274","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
5-hydroxy-7-methoxy-3',4'-diacetoxy-6-(6,6-dimethyl-2-oxo-cyclohexylmethyl)flavone
{"Ingredient_id": "HBIN011655","Ingredient_name": "5-hydroxy-7-methoxy-3',4'-diacetoxy-6-(6,6-dimethyl-2-oxo-cyclohexylmethyl)flavone","Alias": "NA","Ingredient_formula": "C29H30O9","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "10396","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}